Alkeon Capital Management
RARE icon

Alkeon Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Alkeon Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,685,729
Closed -$61.3M – 115
2025
Q2 		$61.3M Hold
1,685,729
– – 0.1% 71
2025
Q1 		$61M Sell
1,685,729
-987
-0.1% -$41.1K 0.13% 68
2024
Q4 		$71M Sell
1,686,716
-1,325,000
-44% -$65.7M 0.14% 60
2024
Q3 		$167M Buy
3,011,716
+769,884
+34% +$39.2M 0.29% 50
2024
Q2 		$92.1M Hold
2,241,832
– – 0.15% 66
2024
Q1 		$105M Hold
2,241,832
– – 0.18% 64
2023
Q4 		$107M Buy
2,241,832
+298,017
+15% +$11.6M 0.24% 53
2023
Q3 		$69.3M Hold
1,943,815
– – 0.12% 70
2023
Q2 		$89.7M Buy
1,943,815
+98,141
+5% +$4.55M 0.16% 67
2023
Q1 		$74M Sell
1,845,674
-8,653
-0.5% -$371K 0.16% 76
2022
Q4 		$85.9M Sell
1,854,327
-357,632
-16% -$14.1M 0.33% 71
2022
Q3 		$91.6M Sell
2,211,959
-256,171
-10% -$13.2M 0.3% 77
2022
Q2 		$147M Buy
2,468,130
+100,000
+4% +$6.15M 0.4% 56
2022
Q1 		$172M Buy
2,368,130
+60,000
+3% +$4.17M 0.34% 67
2021
Q4 		$194M Hold
2,308,130
– – 0.36% 67
2021
Q3 		$208M Buy
2,308,130
+394,482
+21% +$35.7M 0.35% 68
2021
Q2 		$182M Buy
1,913,648
+599,791
+46% +$62.5M 0.27% 74
2021
Q1 		$150M Buy
1,313,857
+3,012
+0.2% +$410K 0.22% 83
2020
Q4 		$181M Sell
1,310,845
-568,375
-30% -$67.4M 0.3% 70
2020
Q3 		$154M Buy
1,879,220
+100,000
+6% +$8.29M 0.29% 62
2020
Q2 		$139M Buy
1,779,220
+158,687
+10% +$10.5M 0.35% 56
2020
Q1 		$72M Buy
1,620,533
+240,000
+17% +$12.5M 0.31% 67
2019
Q4 		$59M Sell
1,380,533
-206,200
-13% -$8.51M 0.22% 81
2019
Q3 		$67.9M Buy
1,586,733
+115,000
+8% +$6.25M 0.24% 79
2019
Q2 		$93.5M Hold
1,471,733
– – 0.37% 58
2019
Q1 		$102M Buy
1,471,733
+652,207
+80% +$37.3M 0.51% 46
2018
Q4 		$35.6M Buy
819,526
+78,205
+11% +$4.27M 0.23% 89
2018
Q3 		$56.6M Buy
741,321
+250,025
+51% +$20.3M 0.27% 71
2018
Q2 		$37.8M Buy
+491,296
New +$31.7M 0.18% 86

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Alkeon Capital Management's RARE Position: Q3 2025 in Review

Alkeon Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 1,685,729 shares — an estimated $61.3M sold.

Alkeon Capital Management first reported a position in RARE in Q2 2018 and held it in 29 quarters. The position peaked at $208M in Q3 2021. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Alkeon Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Alkeon Capital Management sold 1,685,729 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $61.3M.
  • Alkeon Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2018 and held it in 29 quarters.
  • Alkeon Capital Management's Ultragenyx Pharmaceutical position peaked at $208M in Q3 2021.
  • 302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Alkeon Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.